{"id":"NCT03920293","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Na√Øve Adult Patients With Generalized Myasthenia Gravis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-12","primaryCompletion":"2021-05-11","completion":"2023-05-25","firstPosted":"2019-04-18","resultsPosted":"2022-05-26","lastUpdate":"2024-05-28"},"enrollment":175,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Myasthenia Gravis"],"interventions":[{"type":"BIOLOGICAL","name":"Ravulizumab","otherNames":["ALXN1210","Ultomiris"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ravulizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).","primaryOutcome":{"measure":"Change From Baseline In Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score At Week 26","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Ravulizumab","deltaMin":-3.1,"sd":0.38},{"arm":"Placebo","deltaMin":-1.4,"sd":0.37}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.0009"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":106,"countries":["United States","Austria","Canada","Czechia","Denmark","France","Germany","Israel","Italy","Japan","Netherlands","Portugal","South Korea","Spain","Switzerland"]},"refs":{"pmids":["38319212","37103755","36890354","36852670"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=ALXN1210-MG-306&amp;attachmentIdentifier=f164e5fa-8534-413e-a765-e3c6b87e017c&amp;fileName=ALXN1210-MG-306_CSR_Synopsis_redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":86},"commonTop":["Headache","COVID-19","Diarrhoea","Nausea","Arthralgia"]}}